Dose-Escalation Phase I Trial of RG1-VLP for HPV-Associated Cancer Prevention

09 Apr 20264 min read0 viewsINTERVENTIONAL Trial

GIST

This phase I dose-escalation trial evaluates the safety and immunogenicity of RG1-VLP, a candidate vaccine designed to broaden protection against HPV-associated cancers. The study targets healthy women at risk for HPV-related disease and aims to determine a safe and tolerable dose while assessing the vaccine’s ability to provoke an immune response.

RG1-VLP presents an HPV type 16–derived protein with a structural modification relative to the HPV component in Gardasil-9; both vaccines include alum as an adjuvant. The trial protocol contrasts RG1-VLP with existing preventive strategies, including licensed HPV vaccines such as Gardasil-9, to explore relative safety and immunogenicity.

The project acknowledges that Gardasil-9 provides protection against nine HPV types and is FDA-approved for disease prevention, and it notes standard clinical follow-up methods, such as routine cervical screening, as part of current preventive care. Enrollment is planned for 18 participants, with recruitment ongoing and completion anticipated in mid-2027.

The source does not provide outcome data or efficacy comparisons beyond safety and immune response measures, so conclusions on effectiveness relative to current vaccines remain uncertain.

Clinical Editorial

Study Concept and Purpose

This report outlines a first-in-human, dose-escalation Phase I trial evaluating RG1-VLP, a candidate vaccine designed to prevent HPV-associated cancers by eliciting an immune response against additional HPV types not covered by existing vaccines.
The investigation centers on safety, tolerability, and the selection of an optimal dose in healthy women.

Design and Population Snapshot

Study type and aim: Interventional, with primary focus on prevention.
Population: Women without reported cancer, enrolled to assess safety and immunogenicity of RG1-VLP.
Intervention: RG1-VLP containing an HPV16 protein engineered within a virus-like particle framework; uses alum as an adjuvant.
Comparison: Implicitly juxtaposed with standard HPV prevention approaches (e.g., Gardasil-9) as a contextual reference, though not described as a formal comparator arm in this Phase I design.

Vaccine Context and Mechanistic Note

RG1-VLP is positioned as offering protection against rare HPV types not targeted by current vaccines.
The vaccine structure differs slightly from Gardasil-9, which contains multiple HPV proteins and is FDA-approved for HPV-related disease prevention.
Both RG1-VLP and Gardasil-9 employ alum to stimulate immune activity.

Outcomes and Early Signals

Primary outcomes focus on safety and tolerability, plus immunogenicity; no efficacy claims or cancer outcomes are reported at this stage.
The trial seeks to determine whether RG1-VLP can safely invoke an immune response against HPV in healthy participants and how its performance compares with established vaccination approaches.

Operational Details and Timelines

Phase: Phase I, dose-escalation, with the objective of identifying a suitable dose for further testing.
Enrollment target: Approximately 18 participants (estimated).
Status and timeline: Recruiting, with an estimated completion date of mid-2027.